Preventing Cardiovascular Events: Will HDL Therapeutics Change the Treatment Paradigm?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• HDL: A Window of Opportunity in the Mature Cardiovascular Market
• Metabolism and Proposed Atheroprotective Mechanisms of HDL
  • Reverse Cholesterol Transport
  • Antioxidant, Anti-Infl ammatory, and Antithrombotic Effects of HDL
• CETP Inhibitors: The Rise and Fall of Torcetrapib
• Implications of the ILLUMINATE Trial Results
• The Resurgence of Old Concepts
  • New Niacin Formulations
  • New Fibrate Formulations
• The Emergence of New Mechanisms of Action
  • Infusions of Reconstituted HDL/Apo A-I
  • Oral Apo A-I Mimetic Peptides
  • Apo-A-I Synthesis Enhancers
  • ABCA1/ABCG1 Gene Expression Enhancers
• Outlook

Tables

• 1. Lipid and Blood Pressure Changes from Baseline in Phase II and Phase III CETP Inhibitor Studies
• 2. A Selection of Confl icting Publications on the Cardiovascular Benefi ts of CETP Inhibition
• 3. Results from the ILLUMINATE Trial
• 4. Key HDL Therapeutics in the Emerging Drug Pipeline

Figures

• 1. Current Targets for Drugs in the Atherosclerosis Pipeline
• 2. The Reverse Cholesterol Transport Pathway
• 3. Proposed Atheroprotective Mechanisms of HDL
• 4. Opportunity for HDL Therapeutics in Anticipated Primary Indications by Region, 2006